ALNY Stock Chart & Stats
$5549.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$4,721.00 - $8,599.91
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00
Market Cap
$634.41B
Enterprise Value$45.70K
Total Cash (Recent Filing)$3.01B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)62.3
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
28.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.36
Shares Outstanding133,512,570
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7,967.50Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)129.73
Revenue Forecast (FY)$97.14B
Bulls Say, Bears Say
Bulls Say
Cash Generation StrengthMaterial, sustained cash generation (TTM OCF ~$713M; FCF ~$641M) provides durable internal funding for R&D, launches and licensing. Strong FCF growth reduces near‑term financing needs, supports strategic optionality and cushions the business against cyclical revenue swings.
Profitability Inflection And ScaleTransition to consistent profitability and billion‑dollar quarterly product revenue reflects scalable commercial execution and operating leverage. Sustained positive net income and improving margins create a structural cushion that enables reinvestment and reduces existential cash burn risk.
Deep Pipeline And Commercial TractionA broad pipeline (25+ programs) plus accelerating Phase III enrollment and expanding prescriber base provide multiple long‑term value drivers and diversification beyond TTR. This multi‑program approach raises the probability of durable revenue streams and less reliance on a single product.
Bears Say
Rising Royalties Pressuring Gross MarginsIncreasing royalty rates tied to AMVUTTRA materially compress product gross margins as sales scale. This is a structural headwind to long‑term margin sustainability unless offset by price, manufacturing cost reductions, or royalty renegotiation, reducing operating leverage as revenue grows.
Elevated And Rising Operating InvestmentSustained high R&D and SG&A spending to support multiple Phase III programs and launches raises the company’s fixed cost base. If revenue growth decelerates, these elevated investments increase operating leverage risk and could pressure margins and cash flow over a multi‑quarter horizon.
Leverage History And Moderate IndebtednessWhile improved, leverage remains notable with a history of very weak equity. Moderate debt levels reduce financial flexibility for M&A or large investments and raise refinancing and covenant risk if profitability or cash generation weakens, making the balance sheet more sensitive to setbacks.
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $4721.00 and its highest was $8599.91 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $634.41B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 5 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported $26.438 earnings per share for the quarter, beating the consensus estimate of $15.268 by $11.171.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 28.54.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,512,570 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $26.438 in its last earnings report, beating expectations of $15.268. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in MX:ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7,967.50 (― Downside)
$7,967.50 (― Downside)
Blogger Sentiment
Bullish
MX:ALNY Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.73%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Stock 12 Month Forecast
Average Price Target
$7,967.50